Abbott Laboratories $ABT Shares Bought by Rockland Trust Co.

Rockland Trust Co. grew its position in shares of Abbott Laboratories (NYSE:ABT) by 33.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 145,873 shares of the healthcare product maker’s stock after purchasing an additional 36,262 shares during the period. Rockland Trust Co.’s holdings in Abbott Laboratories were worth $13,237,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Nia Impact Advisors LLC grew its stake in shares of Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after buying an additional 79 shares during the last quarter. Riggs Asset Managment Co. Inc. lifted its stake in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 88 shares during the last quarter. GHP Investment Advisors Inc. boosted its holdings in Abbott Laboratories by 0.3% during the 4th quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock valued at $3,685,000 after acquiring an additional 92 shares during the period. Eley Financial Management Inc grew its position in Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares during the last quarter. Finally, Kelleher Financial Advisors increased its stake in Abbott Laboratories by 2.9% in the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after purchasing an additional 93 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance

ABT stock opened at $107.81 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market cap of $186.56 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 2.09 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a 50-day simple moving average of $95.51 and a two-hundred day simple moving average of $100.03.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABT. UBS Group lowered their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. JPMorgan Chase & Co. raised their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Oppenheimer lowered their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Piper Sandler restated an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Diagnostics expansion strengthens growth outlook: Abbott is broadening its Diagnostics growth base through its Exact Sciences relationship and oncology testing expansion. Gains in cancer diagnostics and resilient routine testing are helping offset weaker respiratory-related demand, potentially making growth less dependent on COVID and respiratory testing. Here’s How ABT Broadens Diagnostics Growth Base With Oncology Expansion
• Positive Sentiment: Analysts remain bullish: Although ABT has lagged the broader market over the past year, Wall Street analysts continue to view the stock favorably and see further upside potential based on Abbott’s diversified healthcare portfolio and earnings durability. Abbott Stock: Is Wall Street Bullish or Bearish?
• Positive Sentiment: Reliable-growth investment case: An investor letter from Matrix Asset Advisors presents Abbott as a compelling long-term healthcare holding, emphasizing its dependable growth profile and diversified end markets. Broader nutritional-market growth could also support Abbott’s nutrition business over time. What Makes Abbott Laboratories a Compelling Investment Opportunity Global Nutritional Market Outlook
• Neutral Sentiment: Value debate remains: Comparisons with Envista (NVST) focus on which medical-products stock offers better value. The coverage may prompt investors to weigh Abbott’s premium valuation against its stronger diversification and consistency, but it does not represent a new company-specific catalyst. NVST vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Competitive backdrop: Analysts’ discussion of Abbott alongside other healthcare companies provides sector context, but no major change to Abbott’s outlook is indicated. Boston Scientific’s reduced 2026 guidance could be relatively favorable for Abbott if investors rotate toward companies with steadier execution, though it also underscores competitive pressures in medical devices. Analysts Offer Insights on Healthcare Companies

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.